NCT02983981

Topical Psoriasis Study for Patients Receiving Biologic Therapy

An Open-Label, Observational Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) BID in Psoriasis Patients Being Treated With Biologic Agents

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Psoriasis Treatment Center of Central New Jersey · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks

Detailed description

A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks. Adult male and female subjects with moderate to severe chronic plaque psoriasis All patients will receive Topicort® BID for 4 weeks. After week 4 patients will receive Topicort® BID on two consecutive days a week for 12 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Topicort Topical Spray	open label Topicort spray

Timeline

• Start date: 2016-03-01
• Primary completion: 2016-09-01
• Completion: 2016-10-01
• First posted: 2016-12-06
• Last updated: 2024-03-20
• Results posted: 2018-05-07